https://ri.ufs.br/jspui/handle/riufs/2558 2026-10-30T12:55:40Z 2026-10-30T12:55:40Z Paes, Lizandra Santos Oliveira, Yhago Nascimento de https://ri.ufs.br/jspui/handle/riufs/26201 2026-10-02T12:25:36Z 2026-08-24T00:00:00Z

Title: Interações medicamentosas e incompatibilidades na terapia nutricional parenteral : uma revisão de escopo Authors: Paes, Lizandra Santos; Oliveira, Yhago Nascimento de Abstract: Introduction: Parenteral nutrition (PN) therapy is indicated for patients who may have gastrointestinal tract dysfunction or obstruction, and are unable to meet their nutritional needs via enteral or oral routes. PN therapy is a high-risk feeding modality that may be subject to physicochemical incompatibilities and interactions between medications and nutrients within the parenteral solution bag. Given the complexity of the formulation and the risks associated with incompatibilities and drug interactions, it is relevant to gather and analyze the available evidence on these events in order to contribute to the safety and effectiveness of parenteral nutrition therapy. Objectives: To map the evidence available in the literature regarding drug interactions and incompatibilities related to PN therapy, highlighting the key factors involved, their clinical consequences, and prevention strategies. Methodology: A descriptive and exploratory scoping review was conducted following the Joanna Briggs Institute (JBI) recommendations. The literature search was performed in the PubMed (MEDLINE) database, complemented by strategies adapted for other databases, covering studies published between 2013 and 2026. Results: Evidence showed that a significant portion of PN incompatibilities stems primarily from interactions between electrolytes, such as calcium and phosphate, and the instability of lipid emulsions in "3-in-1" mixtures. Furthermore, studies on medications demonstrated that incompatibility can vary depending on the drug, the PN composition, the "2-in-1" or "3-in-1" system, and the administration method (e.g., addition to the bag vs. Y-site administration). Conclusion: The analyzed studies demonstrate that physicochemical incompatibilities and drug-nutrient interactions pose significant risks to the safety of PN therapy. Preventing these events depends on controlling factors related to the formulation's composition and preparation, as well as pre-assessing the compatibility of concomitantly administered medications. In this context, the pharmacist's role in preventing physicochemical incompatibilities and drug interactions in PN is highlighted.

2026-08-24T00:00:00Z Cruz, Jhenifer Tauany Araújo Andrade, Lara Sousa https://ri.ufs.br/jspui/handle/riufs/26200 2026-10-02T12:19:29Z 2026-08-30T00:00:00Z

Title: Aspectos toxicológicos dos antipsicóticos utilizados em crianças e adolescentes com Transtorno do Espectro Autista (TEA) Authors: Cruz, Jhenifer Tauany Araújo; Andrade, Lara Sousa Abstract: Autism Spectrum Disorder (ASD) is a complex neurodevelopmental condition characterized by persistent deficits in social communication and social interaction, as well as restricted and repetitive patterns of behavior, interests, or activities. The prevalence of ASD has increased over recent decades, making it a significant public health concern. Although behavioral and educational interventions are considered the standard approach for managing ASD symptoms, the use of psychotropic medications is common for the treatment of psychiatric comorbidities and associated behavioral symptoms, such as severe irritability, aggression, hyperactivity, selfinjurious behaviors, and sleep disturbances. This Undergraduate Thesis aims to analyze the toxicological aspects and potential adverse effects associated with the use of psychotropic drugs in children and adolescents with ASD. Particular emphasis is placed on atypical antipsychotics, such as risperidone and aripiprazole, which are the medications most commonly prescribed for the treatment of irritability associated with autism in pediatric populations. A comprehensive review of the analyzed studies demonstrates that, despite the clinical effectiveness of these medications in reducing behavioral symptoms, they present significant toxicological risks that require careful monitoring. The most concerning adverse effects include metabolic syndrome (weight gain, dyslipidemia, and insulin resistance), hyperprolactinemia, extrapyramidal symptoms, sedation, and potential impacts on neuroendocrine development. The discussion highlights the importance of risk-benefit assessment, the challenges of polypharmacy, and the need for monitoring and risk mitigation strategies. It is concluded that individualized therapy and the integration of pharmacological approaches are essential to optimize treatment outcomes and minimize long-term health risks in children with ASD.

2026-08-30T00:00:00Z Santos, Caio Ricardo dos Santana, Matheus Antônio Batista de https://ri.ufs.br/jspui/handle/riufs/26199 2026-10-02T12:16:13Z 2026-08-27T00:00:00Z

Title: Uma revisão de escopo das evidências sobre mecanismos de toxicidade do canabinoide sintético JWH-018, efeitos adversos e risco à saúde pública Authors: Santos, Caio Ricardo dos; Santana, Matheus Antônio Batista de Abstract: Introduction: New psychoactive substances (NPS) constitute a major public health problem due to the rapid expansion of synthetic compounds developed to mimic the effects of traditional drugs. Among these, the synthetic cannabinoid JWH-018 stands out; it is widely found in products marketed as "Spice" or "K2" and is associated with severe intoxications and toxic effects superior to those observed with natural cannabis. Objective: To map and synthesize the available scientific evidence on the mechanisms of toxicity, adverse effects, and public health impacts related to exposure to the synthetic cannabinoid JWH-018. Methodology: A scoping review of a descriptive and exploratory nature was conducted in accordance with the recommendations of the Joanna Briggs Institute (JBI) and the PRISMA-ScR guidelines. The bibliographical search was performed in the PubMed (MEDLINE) database, complemented by strategies adapted for other databases, including studies published between 2022 and 2026. Original articles, reviews, and case reports related to JWH-018 and its toxicological effects were included. Results: The evidence demonstrated that JWH-018 acts as a full agonist of CB1 cannabinoid receptors, presenting greater pharmacological potency than Δ9- tetrahydrocannabinol (THC). Its high affinity for cannabinoid receptors promotes neurochemical alterations associated with neurotoxicity, seizures, cognitive deficits, psychotic episodes, anxiety, aggressiveness, and dependence potential. Furthermore, significant cardiovascular effects were observed, including arrhythmias, hemodynamic changes, myocardial injury, and an increased risk of ischemic events. Hepatic metabolism, mediated primarily by the CYP2C9 enzyme, generates biologically active metabolites capable of prolonging toxic effects and increasing clinical variability among individuals. Significant impacts on public health were also identified, such as an increase in acute intoxications, diagnostic difficulties, limitations in epidemiological surveillance, and regulatory challenges arising from the constant introduction of new synthetic analogs. Conclusion: JWH-018 presents a complex toxicological profile that is significantly more severe than that of natural cannabis, representing a relevant threat to public health. Its neurotoxic, psychiatric, and cardiovascular effects, associated with the formation of active metabolites and the difficulty of laboratory monitoring, reinforce the need to expand toxicological research, strengthen epidemiological surveillance, and develop more effective regulatory and preventive strategies to address the risks related to synthetic cannabinoids.

2026-08-27T00:00:00Z Santos, Marianny Alencar dos Anchieta, Raquel Trindade de https://ri.ufs.br/jspui/handle/riufs/25957 2026-08-28T14:43:48Z 2026-02-12T00:00:00Z

Title: Aplicações da inteligência artificial na farmacovigilância : uma revisão de escopo Authors: Santos, Marianny Alencar dos; Anchieta, Raquel Trindade de Abstract: Introduction: Pharmacovigilance is a strategic area of public health, responsible for identifying, analyzing, and reducing risks associated with the use of medicines. With the advancement of digital systems and the increasing volume of health data, the incorporation of Artificial Intelligence (AI) has emerged as a promising alternative to optimize processes, expand analytical capacity, and strengthen medication safety. In this context, there is a growing need to deepen the understanding of how these technologies are integrated into pharmacovigilance practices. Objective: To map the available scientific evidence on the applications of artificial intelligence in pharmacovigilance activities, identifying the techniques used, purposes, benefits, barriers, and gaps in the literature. Methodology: This is a scoping review conducted in accordance with the Joanna Briggs Institute (JBI) and PRISMA-ScR guidelines. The search was carried out in the PubMed, BVS, SciELO, Web of Science, and Scopus databases, using descriptors related to pharmacovigilance and artificial intelligence, combined with Boolean operators. Studies were selected according to predefined eligibility criteria, with screening performed by independent reviewers. Data were extracted and organized into standardized spreadsheets for descriptive analysis. Results: A total of 3,649 studies were identified, of which 28 were included in the final sample after the screening and eligibility stages. Most publications were concentrated between 2021 and 2025, with a predominance of studies conducted in countries with high technological development. The main AI applications included the detection and prediction of adverse drug reactions, the automated extraction of information from clinical texts, and the automation of processes related to case triage and coding. Among the techniques employed, machine learning, deep learning, and natural language processing were highlighted. The studies reported benefits associated with increased efficiency and improved capacity for detecting safety signals, including reductions of up to 26% in the need for manual signal validation and models achieving AUC values above 0.90 in the automated detection of adverse drug reactions, although limitations related to data quality, model interpretability, and ethical and regulatory challenges were also identified. Conclusion: The results demonstrate that artificial intelligence is being progressively incorporated into pharmacovigilance practices, providing clear benefits in the processing of large volumes of data and in the early identification of risks associated with medication use. Despite the identified potential, the adoption of these technologies is still occurring gradually, requiring greater validation in real-world settings and the strengthening of regulatory frameworks. In this context, artificial intelligence is expected to assume an increasingly strategic role in ensuring medication safety.

2026-02-12T00:00:00Z